1. Home
  2. MRKR vs KTTA Comparison

MRKR vs KTTA Comparison

Compare MRKR & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

23.0M

Sector

Health Care

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.80

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
KTTA
Founded
N/A
2020
Country
United States
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.0M
18.9M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
MRKR
KTTA
Price
$1.30
$0.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.25
$3.00
AVG Volume (30 Days)
115.2K
115.1K
Earning Date
03-18-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$0.28
52 Week High
$4.07
$2.34

Technical Indicators

Market Signals
Indicator
MRKR
KTTA
Relative Strength Index (RSI) 40.44 45.38
Support Level $0.83 $0.67
Resistance Level $1.44 $0.84
Average True Range (ATR) 0.10 0.06
MACD -0.00 0.00
Stochastic Oscillator 20.00 38.69

Price Performance

Historical Comparison
MRKR
KTTA

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Share on Social Networks: